Allotment of 271200 Equity Shares upon Conversion of Warrants.

Date: 16th September, 2026 BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street - Fort, Mumbai — 400 001. Ref.: BSE Scrip Code - 539730 Subject: Outcome of Board Meeting Dated 16th September, 2026 Re: Allotment of 2,71,200 Equity Shares to Non-Promoter upon conversion of Warrants into Equity Shares Dear Sir, This is to inform you that Board of Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on October 22, 2025, had allotted convertible warrants on preferential basis to Allottees on December 29, 2025. Further, we would like to inform that the Warrant Holders have paid the balance of the consideration and have applied for exercising their rights for conversion of 90,400 warrants into 2,71,200 number of Equity Shares. Consequently, the Board of Directors in its meeting held on September 16, 2026 has allotted 2,71,200 Equity Shares of face value Rs. 10/- each to the warrant holder as per following details: Sr. Name of Allottee Category of Total number of Number of Number of No. Investor convertible Equity Shares Warrants warrants allotted upon Outstanding allotted on conversion of for December 29, Warrants on Conversion 2025 April 09, 2026# 1 Alchemy Capital Non- 24,000 54,000 6,000 Management Pvt Ltd Promoter Alchemy Long Term Non- 32,000 72,000 8,000 Ventures Fund, Series Promoter Ajay Kumar Aggarwal Non- 32,000 72,000 8,000 Promoter Divya Aggarwal Non- 8,000 7,200 5,600 Promoter Swati Goel Non- 8,000 12,000 4,000 Promoter Sweta Chokhany Non- 4,000 9,000 1,000 Promoter Vartika Chokhany Non- 4,000 9,000 1,000 Promoter Vivek Dhir Non- 8,000 18,000 2,000 Promoter Ceramet Consultants Non- 4,000 9,000 1,000 Private Limited Promoter Nav Ratan Bhaiya Non- 4,000 9,000 1,000 Promoter TOTAL 90400 271200 37600 # Pursuant to the 1:2 Bonus Issue made by the Company, the entitlement attached to the outstanding warrants stands adjusted in the same proportion as the Bonus Issue, in accordance with the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Accordingly, each outstanding warrant shall be entitled to the corresponding enhanced number of Equity Shares upon exercise, with the exercise consideration being adjusted correspondingly. The allotment of the equity shares shall be made in dematerialized form and the equity shares so allotted shall rank pari passu with the existing Equity Shares of the Company in all respects. The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular dated January 30, 2026 are enclosed as “Annexure I”. The meeting commenced at 06:00 p.m. and concluded at 08:00 p.m. Kindly take the aforesaid information on your records. Thanking you, FOR FREDUN PHARMACEUTICALS LIMITED FREDUN NARIMAN MEDHORA MANAGING DIRECTOR DIN NO.: 01745348 Encl. : Annexure I Annexure I Information as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Issuance of Securities: Sr. Particulars of Securities Details of Securities a) Type of securities proposed to be Equity Shares upon conversion of Warrants into Equity issued Shares of Rs. 10/- each. b) Type of issuance Preferential Issue in accordance with Chapter V of the SEBI ICDR Regulations 2018 and other applicable law c) Total number of securities Allotment of 2,71,200 Fully Paid-Up Equity Shares. proposed to be issued or the total amount for which the securities will be issued In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s): i. Name of Investors Mentioned in the Covering Letter above. ii. Post Allotment of securities - Warrants were allotted on December 29, 2025, carrying outcome of the subscription, the right to subscribe to Equity Shares upon exercise of issue price / allotted price (in the option attached to each warrant, at an issue price of case of convertibles), Rs. 1,250/- per warrant, of which Rs. 312.50/- per warrant, being 25% of the issue price, was payable upfront. Subsequently, pursuant to the 1:2 Bonus Issue made by the Company, the entitlement attached to the outstanding warrants was adjusted in accordance with the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Accordingly, pursuant to such adjustment, 90,400 outstanding warrants were exercisable into 2,71,200 Equity Shares, i.e. three Equity Shares for each outstanding warrant, upon payment of the applicable balance consideration.. iii. No. of Investors 10 (Ten) iv. in case of convertibles - As the total consideration of the 90,400 Convertible intimation on conversion of Warrants is received, the Equity Shares are allotted securities or on lapse of the pursuant to exercise of the conversion of Convertible tenure of the instrument; Warrants. v. Any cancellation or termination Not Applicable proposal for issuance of securities including reasons thereof